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Abstract 
Given the high frequency of activating NOTCH1 mutations, inhibition of the γ-secretase complex 
remains an attractive target for T cell acute lymphoblastic leukemia (T-ALL). However, available 
inhibitors block all four existing γ-secretase complexes equally and lead to severe “on-target” 
gastrointestinal tract, skin and thymus toxicity, limiting their therapeutic applications. Here, we 
demonstrate that genetic deletion or pharmacologic inhibition of Presenilin-1 is highly effective in 
decreasing leukemia whilst avoiding dose-limiting toxicities. Therefore, Presenilin-1 selective 
compounds provide a new therapeutic strategy for safe and effective targeting of T-ALL and should be 
considered for other diseases in which NOTCH signaling plays a role. 
 
 
One Sentence Summary 
Selective inhibition of Presenilin-1 γ-secretase complexes efficiently targets T cell acute lymphoblastic 
leukemia whilst overcoming dose-limiting side-effects observed with complete γ-secretase inhibition.  
 
 
Introduction 
γ-Secretases are a group of widely expressed, intramembrane-cleaving proteases. The enzymes process 
clinical relevant substrates such as APP and NOTCH and have been explored as drug targets in 
Alzheimer's disease, cancer and other disorders (1). However, the clinical use of γ-secretase inhibitors 
(GSIs) has been hampered due to severe mechanism-based dose-limiting toxicity; predominantly 
intestinal goblet cell hyperplasia and concomitant severe diarrhea (2), thymus atrophy and ablated T cell 
development (3, 4), splenic marginal zone atrophy (5) and skin lesions (6). This toxicity is due to 
systemic NOTCH inhibition because NOTCH receptors require γ-secretase complex-mediated 
processing for the release and nuclear translocation of the NOTCH intracellular domain (NICD) in order 
to activate gene expression (7). 
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It is, however, important to realize that the enzymatic activity of the γ-secretase complex reflects the 
combined activity of at least four different complexes. Clinical trials have been performed with broad-
spectrum, non-selective γ-secretase inhibitors that target all four complexes equally. The question 
remains whether inhibition of some but not all γ-secretase complexes, by subunit selective targeting, 
could provide a way forward to safe targeting. 
 
The four different γ-secretase complexes each contain one Nicastrin (NCSTN) and one Presenilin 
enhancer 2 (PEN-2) subunit. In addition, two different APH-1 proteins, APH-1A or APH-1B, and two 
different Presenilin (PSEN) proteins, PSEN1 or PSEN2, exist. One of the APH-1 and one of the PSEN 
proteins combine with the two stable subunits to generate four different subcomplexes, which differ in 
their PSEN subunit and/or APH-1 subunit (8, 9). Different γ-secretase complexes can be expressed 
simultaneously by the same cells and at the same time (1, 10), but differ in their subcellular distribution 
and their biological function (11-13). Indeed, gene targeting of the different complexes revealed a 
variety of different outcomes, going from very severe embryonic lethal Notch phenotypes (7, 14-16), 
over subtle behavioral phenotypes (17, 18), to even normal mice (19). 
 
The γ-secretase complexes have been mainly investigated in the context of Alzheimer’s Disease as they 
process the Amyloid Precursor Protein (APP) to generate different amyloid-β profiles (12). Besides, γ-
secretase inhibitors have been actively investigated as targeted therapeutics for T cell acute 
lymphoblastic leukemia (T-ALL) (20), an aggressive hematologic malignancy resulting from the 
transformation of immature T cell progenitors (21, 22). In T-ALL, activating NOTCH1 mutations are 
the most common mutations observed, present in approximately 60% of all cases (23-25). These 
mutations result in increased and ligand-independent oncogenic NOTCH1 signaling, promoting T cell 
transformation through the physiologic functions of NOTCH1 in the thymus (24, 26). However, like 
physiologic NOTCH1 signaling, oncogenic mutant NOTCH1 signaling still requires γ-secretase 
processing for activation, providing the strong rationale for GSIs as a therapeutic approach for T-ALL 
(20, 27-29). 
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Next to T-ALL, increasing evidence is supporting a causative role for NOTCH gain-of-function 
mutations in solid cancers. These tumors often display inappropriate NOTCH signaling due to 
overexpression of NOTCH receptors and/or ligands or loss of negative regulation of NOTCH signaling 
(30). Because of this, γ-secretase inhibitors were also investigated for a number of hematological and 
solid cancers, including breast cancer, pancreatic cancer, glioma, non-small cell lung cancer and 
colorectal cancer. However, despite extensive research to develop several classes of GSIs, none did 
spare physiologic NOTCH signaling sufficiently and none of these drugs was successful in clinical trials. 
This has led to a halt for the therapeutic development of γ-secretase inhibitors in these areas. The 
hypothesis that selective inhibition of one of the γ-secretase complexes alone, targeting the enzyme most 
active in the tumors while sparing other γ-secretase complexes in the hope to preserve physiological 
Notch signaling in the healthy tissues, has not been tested, however. 
 
Here, we wanted to address whether selective γ-secretase inhibition could be a valid therapeutic 
approach. Given the high frequency of NOTCH1 mutations in T-ALL that result in ligand-independent, 
but γ-secretase dependent signaling, T-ALL provides a perfect model to evaluate this hypothesis. We 
selectively targeted the PSEN1-containing γ-secretase complexes, while leaving the PSEN2-containing 
complexes untargeted. By doing so, we observed a strong clinical efficacy for the treatment of T-ALL 
without the observed toxicity inherent to broad-spectrum GSIs. 
 
Results 
Presenilin-1 is highly expressed in T-ALL and regulates NOTCH1 cleavage 
The Presenilin subunits PSEN1 or PSEN2 provide the catalytic center of the different γ-secretase 
complexes (Fig. 1a). Microarray analysis revealed that both PSEN1 and PSEN2 are expressed during 
human T cell development, albeit PSEN1 is expressed at about four-fold higher levels compared to 
PSEN2 (Fig. 1b). PSEN1 expression is however >30-fold higher than PSEN2 expression in T-ALL cell 
lines and primary T-ALL patient samples (31, 32) (Fig. 1c). NOTCH1 signaling is essential for early T 
cell development in both mice and humans (26, 33), therefore we examined whether Psen1 loss would 
abrogate normal T cell development in mice. Previously, a conditional Psen1 knockout mouse was 
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generated by targeting exon 2/3 (34). We developed a new conditional Psen1 knockout mouse targeting 
exon 1 that also contained a Tag (Psen1f/f) (Fig. S1a) and then crossed this with a CD2Cre transgenic 
mouse (35) to inactivate Psen1 in developing T cells (CD2CrePsen1Δ/Δ mice). The introduction of LoxP 
sites and a Tag into the Psen1 gene locus alone caused a 50% decrease in Psen1 protein expression in 
thymocytes, but did not result in major T cell defects (Fig. 1d-f; Fig. S1b-d). Notably, the complete loss 
of Psen1 expression in thymocytes of CD2CrePsen1Δ/Δ mice did not alter the frequency of major T cell 
populations in the thymus (Fig. 1d-f). Although a small compensatory increase of Psen2 expression was 
seen after loss of Psen1, this was insufficient to overcome the overall loss in γ-secretase complex 
formation assessed by the strong reduction in Nicastrin maturation (Fig. S1b,c). To study the possible 
effect on T cell proliferation, we generated ex vivo cultures of mouse pro-T cells derived from C57BL/6 
wild type, Psen1f/f or CD2CrePsen1Δ/Δ mice (Fig. S2a). These pro-T cells are cultured on Dll4 (Notch1 
ligand)-coated plates and are strictly dependent on Dll4-induced Notch signaling (36). Pro-T cells 
derived from CD2CrePsen1Δ/Δ mice showed comparable proliferation to controls (Fig. 1g), 
demonstrating that Psen1 is dispensable for normal T cell development. Apparently, the presence of 
Psen2 is sufficient to maintain an adequate level of Notch signaling to support normal development. 
 
We next investigated whether Psen1 gene inactivation could affect processing of mutant forms of the 
NOTCH1 receptor found in T-ALL. We transduced the mouse pro-T cells established from C57BL/6 
wild type, Psen1f/f or CD2CrePsen1Δ/Δ mice with a constitutively active and clinically relevant mutant 
NOTCH1 receptor, containing a HD and PEST domain mutation (NOTCH1-L1601P-ΔP). This mutant 
NOTCH1 receptor provides a substrate for γ-secretase, which is independent of ligand stimulation (24). 
C57BL/6 wild type and Psen1f/f derived pro-T cells transduced with mutant NOTCH1 receptors were 
able to survive and proliferate in the absence of Dll4, confirming that the NOTCH1-L1601P-ΔP mutant 
can signal in the absence of Dll4. Interestingly, Psen1 deletion significantly reduced pro-T cell 
proliferation and survival of NOTCH1-L1601P-ΔP expressing cells (Fig. 1h) and decreased mutant 
NOTCH1 receptor processing and NICD1 formation (Fig. 1i). Taken together, these data indicate that 
loss of Psen1 specifically reduces oncogenic NOTCH1 signaling in T cells, whilst having limited effect 
on physiologic Dll4-mediated Notch signaling. 
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Genetic deletion of Presenilin-1 prolongs survival in NOTCH1-induced T cell leukemia in vivo 
Given that loss of Psen1 perturbs the processing and downstream signaling of mutant NOTCH1 
receptors involved in T-ALL, we next assessed if Psen1 deletion could also impair mutant NOTCH1-
induced T-ALL development in vivo. To this end, we transplanted wild type C57BL/6 mice with 
syngeneic wild type C57BL/6, Psen1f/f or CD2CrePsen1Δ/Δ hematopoietic progenitors, expressing 
equivalent levels of ΔEGF-NOTCH1-L1601P-ΔP, inferred from the level of GFP expression, after 
retroviral transduction. (Fig. 2a,b; Fig. S2b). Mice transplanted with wild type or Psen1f/f cells 
transduced with ΔEGF-NOTCH1-L1601P-ΔP showed circulating GFP+ CD4+CD8+ T cells at 6 weeks 
post transplantation, indicative for leukemia development (Fig. 2c,d). Significantly, mice transplanted 
with CD2CrePsen1Δ/Δ cells transduced with ΔEGF-NOTCH1-L1601P-ΔP were largely devoid of 
circulating GFP+ T cells at 6 weeks post transplantation. At 9 weeks, mice transplanted with wild type 
and Psen1f/f cells displayed splenomegaly and thymic enlargement due to CD4+CD8+ leukemic cell 
infiltration, which was still absent in mice transplanted with CD2CrePsen1Δ/Δ cells (Fig. 2e,f; Fig. S2c). 
These differences were not due to impaired homing and engraftment following transplantation of the 
CD2CrePsen1Δ/Δ hematopoietic progenitors (Fig. S2d). Eventually, only 9 out of 17 mice transplanted 
with CD2CrePsen1Δ/Δ progenitors developed CD4+CD8+ leukemia, with a median overall survival of 
120 days compared to 73 and 72 days median survival in wild type and Psen1f/f transplanted mice, 
respectively (p<0.0001, Fig. 2g,h). These data show that deficiency of Psen1 alone is sufficient to 
majorly affect murine T-ALL induction. 
 
Next, we set out to elucidate whether Psen1 loss in an already established leukemia could still impair 
disease progression. To this end, we generated inducible Psen1 conditional knockouts by crossing 
Psen1f/f to Rosa26Cre-ERT2 mice, generating R26Cre-ERT2Psen1f/f mice. C57BL/6 mice were then 
transplanted with R26Cre-ERT2Psen1f/f hematopoietic progenitors transduced with ΔEGF-NOTCH1-
L1601P-ΔP. Following successful engraftment, Psen1 was specifically deleted in transplanted donor 
cells through tamoxifen treatment (100 mg/kg for 5 days). These experiments were performed in primary 
recipient mice and were repeated also in tertiary transplanted recipient mice to assess whether loss of 
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Psen1 in an aggressive leukemia setting still hampers disease progression (Fig. 3a). Analysis of R26Cre-
ERT2Psen1f/f leukemic cells recovered after tamoxifen treatment showed complete ablation of Psen1 
(Fig. S3a). Specific Psen1 deletion in the donor cells reduced leukemia burden, assessed by the fraction 
of circulating GFP+ cells in the peripheral blood, by two-fold at 5 weeks post transplantation and >6-
fold at 9 weeks post transplantation in the primary recipient mice, compared to vehicle-treated mice 
(Fig. 3b). One-week post tamoxifen treatment, analysis of age-matched mice showed that Psen1 deletion 
reduced splenomegaly by 50% compared to vehicle-treated mice (Fig. 3c). Furthermore, Psen1 deletion 
by tamoxifen treatment in an established leukemia increased the median overall survival to 142 days 
compared to 84,5 days for vehicle-treated mice (p<0.0001, Fig. 3d). The tamoxifen treated mice that 
did develop leukemia had lost Psen1, excluding the possibility of having escaped recombination, but did 
show robust Psen2 expression (Fig. S3b). Importantly, tamoxifen treatment had no effect on leukemia 
progression and overall survival in mice transplanted with wild type C57BL/6 tumor cells expressing 
Psen1 endogenously, compared to vehicle controls (Fig. S3c).  
 
Finally, we tested whether Psen1 was required for leukemia maintenance and progression by targeting 
Psen1 in a more aggressive and developed leukemia. Tertiary recipients were transplanted with leukemic 
cells from mice that suffered from full blown leukemia and these tertiary recipients were treated with 
vehicle or tamoxifen. Even in this aggressive leukemia model, Psen1 deletion had a significant effect 
on survival (p<0.001, Fig. 3e). Taken together, these data show the importance of Psen1 in leukemia 
development and maintenance and validate Psen1 as a potential target for therapy in T-ALL cases with 
NOTCH1 mutations.   
 
Pharmacologic inhibition of Presenilin-1 impairs leukemia progression and prolongs survival in vivo 
The significant decrease in leukemic burden identified through genetic loss of Psen1 prompted us to 
investigate whether selective pharmacological PSEN1 inhibition would be a viable strategy for T-ALL 
treatment. To this end, we tested whether the PSEN1-selective inhibitor MRK-560, which has ~100-
fold selectivity over PSEN2 (37) (Fig. S4), could block mutant NOTCH1 receptor signaling in human 
T-ALL cell lines. Indeed, MRK-560 treatment reduced NICD1 generation in HPB-ALL, DND-41 and 
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Jurkat cell lines and resulted in a dose-dependent decrease of proliferation in HPB-ALL and DND-41, 
which depend on NOTCH signaling for their survival (Fig. 4a,b). Jurkat T-ALL cells harbor a PTEN 
deletion and are not dependent on NOTCH signaling for their proliferation which explains why these 
cells do not show a decrease in survival upon MRK-560 treatment (28, 38, 39) (Fig. 4b; Table S2). 
Similar to broad-spectrum γ-secretase inhibitors, the effect of the PSEN1-selective γ-secretase inhibitor 
MRK-560 on proliferation could be attributed to a block in cell cycle (Fig. 4c,d).   
Next, we determined whether pharmacological PSEN1 inhibition impaired T-ALL in vivo. ΔEGF-
NOTCH1-L1601P-ΔP T-ALL lymphoblasts were injected into secondary recipients and treated with 30 
μmol/kg MRK-560 or vehicle for 14 days. MRK-560 treatment resulted in strong anti-leukemic effects 
and improved median survival to 30 days compared to 18 days in vehicle-treated mice (p=0.0009, Fig. 
4e). These data show significant therapeutic effects for pharmacological PSEN1 inhibition in in vitro 
and in vivo T-ALL models. 
 
Having validated selective PSEN1 inhibition in a NOTCH1-driven mouse leukemia model, we next 
investigated the efficacy of PSEN1 targeting in human patient-derived xenograft (PDX) in vivo models. 
Immunodeficient NSG mice were injected with four genetically different PDX T-ALL samples with 
different NOTCH1 mutations (Table S2). Mice were randomized into vehicle and MRK-560 treatment 
arms and were treated with 30 μmol/kg MRK-560 or vehicle for 14 days by subcutaneous injection. 
MRK-560 treatment significantly reduced leukemia burden compared to vehicle treated mice, as 
assessed by peripheral blood counts of human CD45+ cells and in vivo bioluminescence (Fig. 5a-d; Fig. 
S5a-b). The various degree of response to MRK-560 treatment was not explained by differences in 
PSEN1 expression in the PDX models (Fig. S5c). 
 
Analysis of age-matched vehicle versus MRK-560-treated mice at the end of a 2-week treatment period 
showed up to 60% reduction in splenomegaly and up to 40% reduction in leukemic cell infiltration in 
the spleens of MRK-560 treated mice (Fig. 5e-g). Human HLA staining revealed a marked reduction of 
human leukemia cells in the spleen of MRK-560 treated animals compared to vehicle treatment, 
associated with reduced Ki67 staining, in line with reduced leukemia burden and inhibition of 
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proliferation (Fig. S5d,e). Most importantly, MRK-560 treatment significantly prolonged survival 
compared to vehicle treated mice in all three NOTCH1 mutant T-ALL patient samples tested here (1.1 
fold, p=0.0001 for 389E, 1.5 fold, p=0.0011 for XC63 and 1.6 fold, p=0.0027 for XC65; Fig. 5h-j). 
Notably, single agent MRK-560 treatment was still effective even when treatment was initiated in mice 
with a high leukemia burden (“curative setting”), which resembles the clinical setting where disease is 
only detected when blood counts start to change (Fig. 5c,j). In these conditions, a 1,5 fold increased 
survival compared to vehicle treated mice was observed (p=0.0011; Fig. 5j). Moreover, relapsing mice 
also remained sensitive to a second round of MRK-560 treatment indicating no short-term outgrowth of 
an overtly resistant leukemia clone (Fig. S5F). Analysis of leukemic cells following MRK-560 treatment 
showed that canonical NOTCH target genes MYC, DTX1 and NOTCH3 were downregulated in T-ALL 
cells from MRK-560 treated mice compared to vehicle treated mice (Fig. 5k), confirming “on-target” 
effects for MRK-560. 
 
Pharmacological Presenilin-1 selective targeting does not cause gastrointestinal toxicity nor T cell 
developmental defect 
The major hurdle in adopting γ-secretase inhibitors clinically has been the “on-target” NOTCH-related 
toxicity, resulting in severe gastrointestinal goblet cell hyperplasia or defective T cell development. 
Significantly, treatment with the PSEN1-selective γ-secretase inhibitor MRK-560 did not cause any 
pathological changes in the gastrointestinal architecture nor increased numbers of secretory goblet cells, 
assessed by Periodic Acid-Schiff (PAS) staining (Fig. 6a). In contrast, treatment with the classical 
broad-spectrum γ-secretase inhibitor Dibenzazepine (DBZ, 10μmol/kg) resulted in a 4-fold increase in 
the number of secretory goblet cells, characteristic of gastrointestinal toxicity due to systemic NOTCH 
inhibition, as previously reported (2). Moreover, 4 week treatment of wild type mice with intermitted 
dosing of DBZ, as described previously (40), was still more toxic compared to MRK-560 (Fig. S6). The 
expression levels of PSEN1 and PSEN2 within the human small intestine are nearly equivalent (Fig. 6b) 
suggesting that in the absence of PSEN1, the activity of PSEN2 may be sufficient to maintain normal 
gastrointestinal physiology. Furthermore, immunophenotyping revealed no major defects in thymic T 
cell development in healthy C57BL/6 mice treated with MRK-560 for 14 days, with cells progressing 
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normally into CD4+CD8+ T cells (Fig. 6c-e), in line with the genetics experiments shown in Figure 1. 
In contrast, mice treated with DBZ showed defective T cell development, displayed by a marked 
reduction in CD4+CD8+ T cells and an increase in DN1 stage T cells, as previously reported for classical 
γ-secretase inhibitors. Altogether, these data provide evidence for a clear therapeutic window for 
selective PSEN1 targeting in T-ALL.  
 
Discussion 
Activating NOTCH1 mutations are found in approximately 60% of T-ALL patients and across all T-
ALL subtypes (24, 31). Therefore, targeting NOTCH1 by using GSIs that block NOTCH processing 
and activation has been of continuing clinical interest in the treatment of T-ALL. The gastrointestinal 
toxicity inherent to general GSIs ameliorates partially with intermittent dosing regimens; nonetheless, 
the most recent clinical trials were still halted prematurely due to severe adverse effects (2, 6, 41). Here, 
we deliver proof of concept that selective targeting of PSEN1 γ-secretase complexes provides a viable 
and attractive alternative therapeutic approach. Both genetic and pharmacological experiments showed 
consistently that PSEN1 targeting alone is sufficient to strongly mitigate leukemia development, both 
in mutant NOTCH1-driven leukemia mouse models and in human patient-derived xenograft models.  
Using a tamoxifen inducible model for Psen1 deletion, we were able to show that these effects were also 
observed when Psen1 was targeted after leukemia had developed, which more closely resembles the 
clinical situation. Importantly, the beneficial effects of pharmacological Psen1 targeting were also 
observed when treatment was initiated at high blast count, which is classified clinically as higher risk 
with worse prognosis (42, 43). These data show that selective targeting of PSEN1 γ-secretase complexes 
provides a potent approach displaying high anti-leukemic activity, comparable to complete γ-secretase 
inhibition (44). These data are supported by an earlier observation that Psen1 is required for the 
development of a DLL4 driven T-cell lymphoma on a Psen2 null background (45). While that work 
demonstrated that PSEN1 is necessary, it did not demonstrate that it is sufficient to inhibit Psen1 alone 
to block the lymphoma.  Some mice in our experiments, with confirmed Psen1 deletion, still developed 
leukemia likely due to the observed compensatory high Psen2 expression in these cells. Therefore, 
although PSEN2 is not expressed in human T-ALL, reactivation of PSEN2 expression might be a 
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potential resistance mechanism. Interestingly, γ-secretase inhibition can reduce the frequency of 
leukemic stem cells, since mutant NOTCH1 signaling promotes reprogramming to these leukemic stem 
cells (46-49). Although not tested here, our findings suggest that selective PSEN1 targeting might also 
have the promise to target these quiescent and therapy-resistant cells, believed to be responsible for T-
ALL relapse. 
 
Importantly, the selective pharmacological inhibition of Psen1 did not result in gastrointestinal toxicity 
or T cell development defects in mice, opposed to the adverse effects observed by complete γ-secretase 
inhibition by DBZ. Our work extends a previous study in Alzheimer’s disease models where selective 
γ-secretase inhibition was efficacious and tolerable, although treatment periods in these studies were 
significantly shorter than in the current work (37, 50). This lack of toxicity in vivo may find partial 
explanation in the observation that PSEN2 and PSEN1 expression levels are more equivalent within the 
gastrointestinal tract and developing T cells compared to T-ALL cells. Indeed, Psen2-knockout mice 
exposed to MRK-560 did display gastrointestinal and thymus toxicity, comparable to full γ-secretase 
inhibition, indicating that Psen2 is responsible for the protective effects (37). So although Psen2 is 
insufficient to compensate for Psen1 deletion during development (15), sparing Psen2 activity maintains 
physiological relevant signaling in the gut and hematopoietic system during adult life. To completely 
proof that Psen2 activity can compensate for the lack of Psen1 activity, future studies will require a 
complete selective genetic knockout of Psen1 in the gut, e.g. using a villin-Cre mouse model. However, 
for all practical means it is clear that a PSEN1-selective inhibition is highly preferable above the typical 
broad-spectrum inhibition that is induced by the previously tested γ-secretase inhibitors. Thus, in human 
T-ALL cells, PSEN1 expression is significantly higher compared to PSEN2 expression (Fig. 1) and 
PSEN2 expression is likely too low to provide sufficient support for leukemia development. Measuring 
PSEN1/2 expression levels in circulating T-ALL cells might be a helpful parameter to decide whether 
selective PSEN1 targeting might be beneficial. In addition, PSEN1 and PSEN2 complexes have different 
subcellular profiles, resulting in substrate selectivity due to differential compartmentalization (11). 
Therefore, the differential sensitivity for leukemic cells versus normal tissue observed with the PSEN1 
inhibitor might also be partially explained by enzyme-substrate specificity due to different subcellular 
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localization. Further work should determine whether mutant NOTCH1 is processed at the cell surface 
where PSEN1 complexes are predominantly expressed while wild type NOTCH1 is processed 
additionally in endocytic compartments, where PSEN2 complexes reside (11). 
 
Our study is conducted using preclinical experimental models that may not completely recapitulate their 
human counterparts. The murine leukemia models used were solely driven by mutant NOTCH1 
signaling, whereas patients diagnosed with leukemia often display multiple different genetic lesions. 
However, the four human PDX samples used to determine the potency of pharmacological PSEN1-
selective targeting displayed various mutational backgrounds, strengthening our preclinical findings. In 
addition, human PDX models have shown concordance between preclinical results and corresponding 
available clinical data (51), making them a good model to study new potential therapeutic approaches. 
In any event, the overall increased safety profile of selective PSEN1 γ-secretase inhibition warrants 
optimism for further clinical development. Carefully monitoring of thymus, gastrointestinal tract, and 
also skin, which is known to be sensitive for tumorigenesis when Psen1 is deleted (6, 52), will be 
necessary when further addressing the clinical feasibility of Psen1 selective targeting in patients. 
 
Finally, if further proof of concept can be established in T-ALL patients, even more applications for 
selective γ-secretase inhibition in the clinic could be envisaged. Indeed, safe selective γ-secretase 
inhibition might be useful as additional therapy in a variety of other cancers with deregulated NOTCH 
signaling, such as B-cell lymphoma, breast cancer and glioma (53-55). Furthermore, clinical interest in 
γ-secretase inhibition might become revived in other therapeutic areas where development was stopped 
because of gastrointestinal side effects, such as acute hearing loss (56, 57); peritoneal fibrosis as a 
complication of dialysis in renal disease (58); and atherosclerosis (59, 60). 
 
 
Materials and Methods 
Study design. We hypothesized that selective targeting of specific γ-secretase subunits is a safe strategy 
to target NOTCH1 mutant T cell acute lymphoblastic leukemia. Cell culture experiments using cell lines 
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were performed at least three times. Ex vivo T cell cultures were performed using at least three different 
mice to generate pro-T cells from, unless otherwise noted. For treatment studies involving mice, disease 
burden was determined at treatment initiation and animals were rank-ordered and divided into treatment 
arms after assuring that mean disease burden was comparable among groups. For toxicity studies in 
mice, animals were randomly assigned to treatment groups. Sample sizes were chosen based on prior 
experience and power calculations of expected differences with this type of experiments. Sample sizes 
for in vivo experiments were increased to account for variation among mice. Initial bone marrow 
transplants were replicated to test for variation in leukemia progression among different experiments. 
After this was ruled-out, bone marrow transplantation experiments were no longer replicated, but sample 
size was large and results were reproducible among animals. For testing the effect of MRK-560 on 
human PDX samples in mice, every experiment was performed only once with five mice per treatment 
intervention. However, three independent PDX samples were chosen to ensure reproducibility among 
different patient samples to test for a broader applicability of the approach. Once conditions for an 
experiment were optimized, all data were included in the absence of a specific technical or procedural 
reason that confounded the interpretation of a finding. For bioluminescence imaging, the value from one 
vehicle mouse on day 21 was excluded from the analysis, due for technical reasons due to an incorrect 
IP injection. Bioluminescence values for this mouse before and after day 21 are present in the analysis. 
For histological analysis for intestinal toxicity, investigators were blinded during goblet cell counting. 
During data collection and analysis investigators were blinded to group allocation. 
 
Cell culture, expression plasmids and retrovirus production. HPB-ALL, DND41 and Jurkat cell 
lines were cultured in RPMI medium supplemented with 20% Fetal Bovine Serum (FBS). HEK293T 
cells were cultured in RPMI medium supplemented with 10% FBS. Mouse Embryonic Fibroblasts 
(MEFs) knockout for Psen and Aph1 rescued with PSEN1 and APH1A or PSEN2 and APH1A expression 
were described previously (12). MEFs were transduced with pMSCV-NOTCH1ΔE-RFP-puromycin 
viral vectors and after puromycin selection, RFP-positive cells were selected through FACS sorting and 
cultured in DMEM/F12 medium supplemented with 10% FBS. All other constructs used were cloned 
into the pMSCV-IRES-GFP vector. Viral vectors were produced in HEK293T cells using an EcoPack 
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packaging plasmid and Genejuice transfection reagent (Merck-Millipore) and virus was harvested 48 h 
post transfection. The stromal cell-free culture system used to generate mouse pro-T cells was described 
previously (36, 61) and is summarized in supplement.  
 
Compounds. DAPT was a kind gift from Janssen Pharmaceutica and DBZ ((S)-2-(2-(3,5-
Difluorophenyl)acetamido)-N-((S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl) 
propanamide) was purchased from Selleckchem. Dimethylsulphoxide (DMSO) was purchased from 
VWR and (2-Hydroxypropyl)-β-cyclodextrin, meglumine, corn-oil and tamoxifen were purchased from 
Sigma-Aldrich. MRK-560 (N-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-
trifluoro methanesulfonamide)  was kindly provided by Janssen Pharmaceutica and synthesized as 
described in supplement (62).  
 
Gene expression profiling. Human thymocytes were extracted from thymus tissue from children 
undergoing cardiac surgery and were obtained and used according to the guidelines of the Medical 
Ethical Commission of the Ghent University Hospital, Belgium. Fluorescence-activated cell sorter 
(FACS)-mediated cell sorting was used to isolate the different thymocyte subsets, representing the 
different stages of normal T cell development, as described previously (63, 64). 
 
GEO accession codes for publicly available datasets. Data for PSEN1 and PSEN2 expression in 
human small intestine was obtained from the GTEx portal and dbGaP accession number 
phs000424.vN.pN. RNA-sequencing data from T-ALL cell lines and T-ALL patient samples was 
published previously (31, 32). RNA-sequencing data on T-ALL cell lines is available in the EGA 
database with accession number EGAD00001000849. RNA-seq data for human T-ALL can be accessed 
at https://ocg.cancer.gov/programs/target/data-matrix. 
 
Mice and animal procedures. All experiments were approved by the Ethical Committee on Animal 
Experimenting of the University of Leuven. The generation of the different strains is described in. 
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supplement. Bone marrow transplantation to generate the mouse model for ΔEGF-NOTCH1-L1601P-
ΔP was performed as described (65). 
 
Patient-derived xenografts. Human leukemic bone marrow cells from NOTCH1 mutant T-ALL 
patients 389E, XC63, XC65 and XB47 (Supplementary Table S2) were injected into the tail vein of 6 
to 12 week old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. After successful engraftment, 
splenocytes were harvested and reinjected at a concentration of 1×106 cells into secondary recipient 
NSG mice to create secondary transplants. Human leukemic cells were identified in peripheral blood 
samples by anti-hCD45 (APC, eBioscience) staining by flow cytometry or by luciferase in vivo 
bioimaging using the IVIS Spectrum (Caliper Lifesciences). After the leukemic clone was detectable in 
the blood or by bioimaging, mice were segregated randomly into treatment groups and treated daily for 
14 days with vehicle or MRK-560 (30 μmol/kg) dissolved in 20% hydroxypropyl-β-cyclodextrin 
(HPβCD) in 0.1 M meglumine by subcutaneous injection.  
 
Statistical analyses. Graphs are presented as mean ± standard deviation and all analysis were performed 
using GraphPad Prism. Comparison between two groups was performed by the Student’s unpaired two-
tailed t test. One-way Anova was used to examine differences when comparing effects in three groups, 
i.e. comparing wild type, Psen1f/f and CD2CrePsen1Δ/Δ for leukemia progression, T cell development 
and in ex vivo T cell cultures. For measuring cell growth of T-ALL cells or leukemia progression in 
patient-derived xenograft models over time, differences were assessed by two-way Anova. Tukey post-
hoc analysis was performed to correct for multiple comparisons. Survival in mouse experiments was 
represented with Kaplan-Meier survival curves and statistical significance was calculated using the log-
rank test.  
 
 
List of Supplementary Materials 
Supplementary Methods 
Fig. S1. Psen1 deletion does not affect T cell development. 
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Fig. S2. Psen1 deletion does not affect engraftment in bone marrow transplants. 
Fig. S3. Tamoxifen does not affect leukemia progression 
Fig. S4. MRK-560 shows selectivity for PSEN1 over PSEN2. 
Fig. S5. Treatment of patient-derived xenograft samples with MRK-560 
Fig. S6. Long term treatment with MRK-560 leads to significantly less gastrointestinal toxicity 
compared to DBZ 
Table S1. Primers used for qPCR 
Table S2. T-ALL patient-derived xenograft samples 
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Figure legends 
 
Fig. 1. Psen1 deletion specifically reduces oncogenic mutant NOTCH1 signaling in T cells.  
(A) Schematic representation of the four different γ-secretase complexes that exist in humans. All 
complexes contain Nicastrin (NCSTN), Presenilin-enhancer-2 (PEN-2) and either APH-1A or APH-1B 
and Presenilin-1 (PS-1) or Presenilin-2 (PS-2). (B) PSEN1 (probe X203460_s_at) and PSEN2 (probe 
X211373_s_at) expression in sorted subsets of human thymocytes. Average expression and standard 
deviation in samples obtained from two different donors are shown. (C) RNA-sequencing FPKM PSEN1 
and PSEN2 levels in T-ALL cell lines (ALL-SIL, CCRF-CEM, DND41, HPB-ALL, HSB2, Jurkat, 
Karpas45, KE37, LOUCY, MOLT14, MOLT4, P12-Ichikawa, PEER, PF382, RPMI-8402, RM2, 
SUPT1, SUPT13 & T-ALL1) and T-ALL patient samples. (D) Representative flow-cytometry plots of 
thymocyte populations stained with antibodies against CD4 and CD8 or CD44 and CD25 in C57BL/6 
wild type, Psen1f/f or CD2CrePsen1Δ/Δ mice. (E, F) Quantification of thymic T cell populations in 
relative numbers (wild type: n=5, Psen1f/f: n=4, CD2CrePsen1Δ/Δ: n=4). (G) Relative cell numbers of ex 
vivo cultures of mouse pro-T cells derived from C57BL/6 wild type, Psen1f/f or CD2CrePsen1Δ/Δ mice 
grown for 7 days (n=3 for all). (H) Relative cell numbers of ex vivo cultures of mouse pro-T cells derived 
from C57BL/6 wild type (n=2), Psen1f/f (n=3) or CD2CrePsen1Δ/Δ (n=3) mice transduced with MSCV-
NOTCH1-L1601P-ΔP-IRES-GFP grown for 7 days without Dll4 Notch ligand. (I) Western blot analysis 
of C57BL/6 wild type (n=4), Psen1f/f (n=4) or CD2CrePsen1Δ/Δ (n=3) NOTCH1-L1601P-ΔP pro-T cells 
for NICD1, Psen1, Psen2, Nicastrin and β-actin cultured in the absence of Dll4 for 72 hours. 
Quantification of NICD1 levels are shown on the right. NICD, Notch IntraCellular Domain. All graphs 
show the mean values and error bars represent standard deviation. P-values for C were calculated using 
two-tailed Student’s t-test. **** P ≤ 0.0001. P-values in E, F, G, H and I were calculated using one-
way ANOVA. * P ≤ 0.05, *** P ≤ 0.001 and **** P ≤ 0.0001. 
 
Fig. 2. Psen1 deletion impairs mutant NOTCH1-induced T-ALL development.  
(A) Schematic of primary bone marrow transplant using hematopoietic stem and progenitor cells from 
C57BL/6 wild type, Psen1f/f or CD2CrePsen1Δ/Δ donor mice transduced with MSCV-ΔEGF-NOTCH1-
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L1601P-ΔP-IRES-GFP transplanted into sublethally irradiated wild type C57BL/6 recipient mice. (B) 
Representative flow cytometry plots for the levels of GFP+ transduced lineage-negative cells prior to 
injection into recipient mice, (C) Representative flow cytometry plots for levels of circulating GFP+ 
cells in peripheral blood from mice transplanted with wild type, Psen1f/f or CD2CrePsen1Δ/Δ progenitors 
expressing ΔEGF-NOTCH1-L1601P-ΔP 6 weeks after transplantation. Quantification of the GFP+ 
population is shown on the right (n=9, 14 and 14 mice, respectively). (D) Representative flow cytometry 
plots of peripheral blood stained with antibodies to CD4 and CD8 from mice transplanted with wild 
type, Psen1f/f or CD2CrePsen1Δ/Δ progenitors expressing ΔEGF-NOTCH1-L1601P-ΔP 6 weeks after 
transplantation. Quantification of the CD4+CD8+ double-positive (DP) population is shown on the right 
(n=9, 14 and 14 mice, respectively). (E) Size and weight of spleens from mice transplanted with wild 
type, Psen1f/f or CD2CrePsen1Δ/Δ progenitors expressing ΔEGF-NOTCH1-L1601P-ΔP 9 weeks after 
transplantation (n=3). (F) Quantification of GFP+ cells in spleens from mice transplanted with wild type, 
Psen1f/f or CD2CrePsen1Δ/Δ progenitors expressing ΔEGF-NOTCH1-L1601P-ΔP 9 weeks after 
transplantation (n=3). (G) Kaplan-Meier survival curves of mice transplanted with wild type, Psen1f/f or 
CD2CrePsen1Δ/Δ progenitors expressing ΔEGF-NOTCH1-L1601P-ΔP progenitors. All graphs show the 
mean values and error bars represent standard deviation. (H) Representative flow cytometry of end stage 
leukemia in the different cohorts of mice. P-values in C, D, E and F were calculated using one-way 
ANOVA. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001. P-value in F was calculated using 
the log-rank test. **** P ≤ 0.0001. 
 
Fig. 3. Genetic targeting of Psen1 impairs mutant NOTCH1 leukemia maintenance.  
(A) Schematic of primary bone marrow transplant using hematopoietic stem and progenitor cells from 
R26Cre-ERT2Psen1f/f donor mice transduced with MSCV-ΔEGF-NOTCH1-L1601P-ΔP-IRES-GFP 
before transplantation into sublethally irradiated wild type C57BL/6 recipient mice. Following 
confirmed engraftment (3 weeks post transplantation), primary transplant mice either were treated with 
100 mg/kg/day tamoxifen by IP injection on 5 consecutive days to delete Psen1 specifically in 
transplanted donor cells or vehicle or used for secondary/tertiary transplants prior to treatment with 100 
mg/kg/day tamoxifen by IP injection on 5 consecutive days to delete Psen1. (B) Levels of circulating 
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GFP+ cells in peripheral blood from mice transplanted with R26Cre-ERT2Psen1f/f progenitors expressing 
ΔEGF-NOTCH1-L1601P-ΔP following tamoxifen or vehicle treatment 5 weeks (n=13 and n=14 mice, 
respectively) and 9 weeks post-transplant (n=9 and n=11 mice, respectively). (C) Spleen weight and 
quantification of GFP+ cells in spleens from mice transplanted with R26Cre-ERT2Psen1f/f progenitors 
expressing ΔEGF-NOTCH1-L1601P-ΔP 5 weeks after transplant, treated either with vehicle only or 
tamoxifen (n=3 mice). (D) Kaplan-Meier survival curves of primary R26Cre-ERT2Psen1f/f transplant 
mice expressing ΔEGF-NOTCH1-L1601P-ΔP treated either with vehicle or tamoxifen. (E) Kaplan-
Meier survival curves of tertiary R26Cre-ERT2Psen1f/f mice expressing ΔEGF-NOTCH1-L1601P-ΔP 
treated either with vehicle or tamoxifen. Gray boxes represent treatment period. All graphs show the 
mean values and error bars represent standard deviation. P-values in B and C were calculated using two-
tailed Student’s t-test. ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001. The P-value in D was calculated 
using the log-rank test. **** P ≤ 0.0001.  
 
Fig. 4. Presenilin-1 selective inhibition impairs T-ALL cell proliferation.  
(A) Western blot analysis for NICD1 levels in HPB-ALL, DND41 and Jurkat cells in response to MRK-
560 and DAPT treatment. (B) Proliferation of NOTCH-dependent HPB-ALL and DND41 cells and 
NOTCH-independent Jurkat cells in response to MRK-560 (n=3). (C) Cell cycle analysis of HPB-ALL 
cells treated with increasing doses of MRK-560. (D) Quantification of the percentage of cells in G1 
phase of HPB-ALL and DND-41 cells upon treatment with increasing doses of MRK-560. (E) Kaplan-
Meier survival curves for mice with ΔEGF-NOTCH1-L1601P-ΔP-induced leukemia treated with 
vehicle or 30μmol/kg/day MRK-560 for 14 days. Gray boxes represent treatment period. Graphs show 
the mean values, error bars represent standard deviation. P-values in B were calculated using two-way 
Anova, P-values in C were calculated using the log-rank test, * P ≤ 0.05, ** P ≤ 0.01 and **** P ≤ 
0.0001.  
 
Fig. 5. Pharmacological Psen1 inhibition attenuates leukemia in patient-derived xenografts. 
Progression of human-CD45+ cells in peripheral blood from mice transplanted with patient sample (A) 
389E, (B) XC63 and (C) XC65 treated with vehicle or 30μmol/kg/day MRK-560 for 14 days. (D) 
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Representative bioluminescence images depicting mice with leukemia burden closest to the mean for 
mice transplanted with patient sample XC65, treated with vehicle or MRK-560 for 14 days and 
quantification in the right panel. (E,F,G) Spleen weight and quantification of human-CD45+ cells in 
spleens from mice transplanted with patient sample (E) 389E, (F) XC63 and (G) XC65 after 14 days 
treatment with vehicle or MRK-560 (n=3 for 389E and n=4 for XC63 and XC65). (H,I,J)  Kaplan-Meier 
survival curves of mice transplanted with patient sample (H) 389E, (I) XC63 and (J) XC65 treated with 
vehicle or MRK-560 for 14 days with XC65 showing survival curve when MRK-560 treatment was 
started once leukemia burden was shown to be high in blood (~50% hCD45+ cells) (K) qPCR analysis 
of DTX1, NOTCH3 and MYC expression levels in splenocytes from mice transplanted with patient 
sample XC63 or XC65 after 14 days vehicle or MRK-560 treatment (n=4). Graphs show the mean 
values, error bars represent standard deviation. Gray boxes represent treatment period. P-values in A, B, 
C and D were calculated using two-way Anova and two-tailed Student’s t-test, P-values in E, F, G and 
K were calculated using two-tailed Student’s t-test and P-values in H, I and J were calculated using the 
log-rank test, ** P ≤ 0.01, *** P ≤ 0.001 and  **** P ≤ 0.0001.  
 
Fig. 6. Pharmacological selective Psen1 targeting does not cause gastrointestinal toxicity or T cell 
developmental defects.  
(A) Representative images of Periodic Acid-Schiff staining of intestines from mice treated with vehicle, 
MRK-560 or the broad-spectrum γ-secretase inhibitor Dibenzazepine (DBZ) for 14 days to assess the 
number of secretory goblet cells. Scale bars represent 100 μm. Quantification of the number of goblet 
cells per cm villus is shown on the right (vehicle n=4, MRK-560 n=4 and DBZ n=3, respectively). (B) 
PSEN1 and PSEN2 gene expression levels in small intestine. Data for this analysis was obtained from 
the GTEx portal and dbGaP accession number phs000424.vN.pN. (C) Representative flow-cytometry 
plots of thymocyte populations stained with antibodies to CD4 and CD8 or CD44 and CD25 in C57BL/6 
mice treated with vehicle, MRK-560 or Dibenzazepine (DBZ) for 14 days. (D, E) Quantification of 
intrathymic T cell populations in relative numbers (vehicle n=5, MRK-560 n=5 and DBZ n=3, 
respectively). All graphs show the mean values, error bars represent standard deviation. The P-values in 
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A, D and E were calculated using one-way ANOVA. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** 
P ≤ 0.0001. 
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Supplementary Methods 
 
Chemistry. MRK-560 (N-[4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-
trifluoro methanesulfonamide)  was kindly provided by Janssen Pharmaceutica and synthesized as 
follows. 4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexanamine was synthesized using the 
literature procedure (61). Trifluoromethanesulfonic anhydride (0.214 mL, 1.269 mmol) was added to a 
stirred solution of 4-(4-chlorophenyl)sulfonyl-4-(2,5-difluorophenyl)cyclohexanamine (200 mg, 0.518 
mmol) and triethyl amine (0.177 mL, 1.273 mmol) in anhydrous dichloromethane (10 mL) at 0 °C and 
the reaction mixture was stirred further for 90 min under inert atmosphere. Upon completion (TLC), 
reaction mixture was warmed to ambient temperature and concentrated in vacuo. The residue was then 
diluted with ethyl acetate (50 mL), washed with 2N NaOH, water, brine, dried over anhydrous 
magnesium sulfate, filtered and concentrated in vacuo. The crude compound was purified by flash 
column chromatography using 15% ethyl acetate in n-heptane as eluent to afford the desired compound 
as colourless solid (215 mg, 80%). 1H NMR (400 MHz, DMSO-d6): 1.49 (br t, J=13.8 Hz, 2 H), 1.82 
(br d, J=14.2 Hz, 2 H), 2.33 - 2.46 (m, 2 H), 2.52 - 2.62 (m, 2 H), 3.61 - 3.67 (m, 1 H), 7.11 - 7.24 (m, 
2 H), 7.29 - 7.34 (m, 1 H), 7.34 - 7.39 (m, 2 H), 7.61 - 7.65 (m, 2 H), 9.76 (br d, J=5.3 Hz, 1 H) δ ppm. 
13C NMR (100 MHz, DMSO-d6): 23.94 (br d, J=5.1 Hz, 1 C), 27.61 (br s, 1 C), 49.14 (s, 1 C), 69.90 
(d, J=4.4 Hz, 1 C), 117.89 - 118.41 (m, 1 C), 118.42 - 118.76 (m, 1 C), 118.97 (dd, J=26.0, 4.0 Hz, 1 
C), 120.76 (dd, J=11.7, 7.3 Hz, 1 C), 129.09 (s, 1 C), 131.66 (s, 1 C), 133.23 (s, 1 C), 139.56 (s, 1 C), 
156.66 - 157.52 (m, 1 C), 159.54 (dd, J=62.7, 1.8 Hz, 1 C) δ ppm. 19F NMR (377 MHz, DMSO-d6): 
117.99 (s, 1 F), -113.25 (s, 1 F), -77.39 (s, 1 F) δ ppm. LCMS (ESI): 535.1 [M+NH4]+, 516.1 [M-H]- 
Purity: 99% (retention time: 2.20 min). 
 
Antibodies for Western blotting. Rabbit polyclonal antibodies against Aph1a (B80.3), Aph1b (B78.2), 
Nct (9C3) and Pen‐2 (B126) were described previously (66, 67). Rabbit anti-Cleaved-Notch1-Val1744 
(D3B8), anti-Psen1-CTF (D39D1) and anti‐Psen2‐CTF (D30G3) were purchased from Cell Signaling, 
Mouse anti‐beta‐actin (A5441) from Sigma and Rabbit anti-tRFP (AB234) was from Evrogen. 
35 
 
Secondary antibodies were conjugated with horseradish peroxidase and bands were visualized using a 
cooled charge-coupled device camera (ImageQuant LAS-4000; GE Healthcare). 
 
Western blotting. MEFs, T-ALL cell lines or single cell preparation from mouse tissues were lysed in 
STE buffer (250 mM sucrose, 5 mM Tris pH7, 1 mM EGTA) + 1% TX‐100 and incubated on ice for 
30 min. The supernatant was collected after centrifugation at 19,000 g for 30 min at 4 °C. Equal amounts 
of protein were separated on NuPAGE NOVEX Bis-Tris gels (Life Technologies).  
 
Presenilin selectivity assay. MEFs cells expressing the specified γ-secretase complexes were treated 
with the different compounds as indicated for 18 h in DMEM/F12 supplemented with 2% FBS.  
 
Ex vivo T cell cultures. Bone marrow cells were isolated from femur and tibia. Lineage-negative cells 
were enriched by negative selection using biotinylated antibodies directed against non-hematopoietic 
stem cells and non-progenitor cells (CD5, CD11b, CD19, CD45R/B220, Ly6G/C(Gr-1), TER119, 7-4) 
and streptavidin-coated magnetic particles (RapidSpheres™, STEMCELL Technologies). Enriched 
cells were cultured on Dll4-Fc coated plates in the presence of mIL7 (20 ng/mL) and mSCF (20 ng/mL). 
After differentiation into DN2 stage pro-T cells (CD44+CD25+), cells were transduced with MSCV-
NOTCH1-L1601P-ΔP-IRES-GFP and GFP-positive cells were sorted through FACS sorting (S3 cell 
sorter Bio Rad). To assess processing and signaling from transduced mutant NOTCH proteins, cells 
were cultured in the absence of Dll4 during the course of experiments unless stated otherwise.   
 
Human primary leukemia samples. Clinical leukemia samples were obtained with informed consent 
at local institutions and all experiments were conducted on protocols approved by the Ethical Committee 
of the University of Leuven.  
 
Mice and animal procedures. Psen1 conditional knockout mice (Psen1tm2.1Bdes) were generated by 
homologous recombination in E14 ES cell line by introducing two loxP sites flanking exon 1. The first 
loxP site was introduced in intron 1 and the second together with a Frt flanked Hygromycin B selection 
marker cassette in intron 2. In addition, a double tag encoding Calmodulin Binding Protein (CBP) and 
3xFLAG was inserted immediately following the ATG start codon. F1 offsprings were crossed with 
Gt(ROSA)26Sortm1(FLP1)Dym strain and deletion of the selection cassette was confirmed by Southern 
Blotting and PCR analysis. To generate mice carrying a Psen1 deletion in all committed B and T cell 
progenitors, we crossed these mice harboring the conditional Psen1 targeted allele with a specific Cre 
deleter line B6.Cg-Tg(CD2-icre)4Kio/J (The Jackson Laboratory, #008520), generating 
CD2CrePsen1Δ/Δ. To generate conditional inducible Psen1 knockout mice, we bred animals harboring 
the conditional Psen1 allele with B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J mice, which express a 
tamoxifen-inducible form of the Cre recombinase, generating Rosa26Cre-ERt2Psen1f/f mice. All 
36 
 
colonies were kept on an inbred C57Bl/6J background, which were also used as wild type control 
animals and recipient animals for primary and secondary transplants. NOD.Cg-Prkdscid Il2rgtm1Wjl 
H2-Ab1tm1Gru Tg(HLA-DRB1)31Dmz/Szj (NSG) mice used for patient-derived xenograft 
experiments were purchased from Harlan Laboratories. During experiments mice were housed in 
individually ventilated cages enriched with wood‐wool and shavings as bedding, given access to water 
and food ad libitum and monitored daily. 
 
Murine bone marrow transplantation. Six to 12 week old male mice were sacrificed and bone marrow 
cells were harvested from femur and tibia. Lineage-negative cells were enriched by negative selection 
using biotinylated antibodies directed against non-hematopoietic stem cells and non-progenitor cells 
(CD5, CD11b, CD19, CD45R/B220, Ly6G/C(Gr-1), TER119, 7-4) and streptavidin-coated magnetic 
particles (RapidSpheres™, STEMCELL Technologies) and cultured overnight in RPMI with 20% FCS 
with IL3 (10 ng/mL, Peprotech), IL6 (10 ng/mL, Peprotech), SCF (50 ng/mL, Peprotech), and penicillin-
streptomycin. The following day, 1x106 cells were transduced by spinoculation (90 min at 2500 rpm) 
with viral supernatant (ΔEGF-NOTCH1-L1601P-ΔP) and 8 μg/mL polybrene. The following day, the 
cells were washed in PBS and injected (1×106 cells/0.3 mL) into the lateral tail vein of sublethally 
irradiated (5 Gy) syngeneic 8 to 12 week old female C57BL/6 recipient mice. For secondary transplants, 
leukemic T cells were obtained from splenic tissue derived from mice transplanted with ΔEGF-
NOTCH1-L1601P-ΔP wild type cells. Following isolation, 1,000,000 cells were transplanted 
intravenously into sublethally irradiated (2.5 Gy) 8 to 10 week old wild type (C57BL/6) female recipient 
mice. To delete the Psen1 gene in NOTCH1-induced mouse leukemia, animals were treated with 100 
mg/kg tamoxifen by IP injection for 5 consecutive days.  
 
In vivo imaging. For in vivo bioimaging, cells from NOTCH1 mutant T-ALL sample XC63 were 
injected into the tail vein of 6 to 12 week old NSG mice and human leukemic cell expansion was 
monitored through hCD45 staining on peripheral blood samples. After successful engraftment and 
leukemic disease development, mice were sacrificed and single cells were isolated from the spleen, 
containing >90% hCD45+ cells. Splenocytes were transduced overnight with lentivirus pCH-SFFV-
eGFP-P2A-fLuc and GFP-positive cells were sorted using a S3 Sorter (Bio-Rad) before being 
transplanted back into NSG mice via tail vein injection. Upon confirmation that leukemic cells were 
>95% GFP-positive, leukemic cells were isolated from spleen and re-transplanted into a larger cohort 
of NSG mice for treatment studies. For in vivo bioluminescence imaging, anesthesia was induced in an 
induction chamber with 2% isoflurane in 100% oxygen at a flow rate of 2 L/min and maintained in the 
IVIS with a 1.5% mixture at 0.5 L/min. Before each imaging session, the mice were injected 
subcutaneous with 126 mg/kg d-luciferin (Promega, Leiden, the Netherlands) dissolved in PBS 
(15 mg/mL). Next, they were positioned in the IVIS and consecutive 2 min frames were acquired until 
the maximum signal was reached. Data are reported as the total flux per second from the whole mouse. 
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Toxicity studies, immunohistochemistry, immunofluorescence and flow cytometry. Healthy 12 
week old C57BL/6 mice were treated for 14 days with vehicle (20% hydroxypropyl-β-cyclodextrin 
(HPβCD) in 0.1 M meglumine) or 30 μmol/kg MRK-560 by subcutaneous injection or 10 μmol/kg DBZ 
or vehicle (0.5% Methylcellulose, 0.1% Tween80) by IP injection. For the intermittent 4 week treatment, 
C57BL/6 mice were treated with the same concentrations of DBZ and MRK-560 but at a 5-day on/2-
day off schedule. After treatment, thymus was isolated and single cells were prepared and stained for 
CD4, CD8, CD44 and CD25 to assess T cell development. To assess goblet cell hyperplasia, intestines 
from treated NSG mice were harvested and flushed with PBS and 10% neutral buffered formalin prior 
to fixation. For every mouse, a minimal of 10 villi were assessed for the number of secretory goblet 
cells. In addition, total body weight from all treated mice was assessed during and after treatment.   
 
Immunohistochemistry. Tissues were collected and fixed in 10% neutral buffered formalin (Sigma) 
for 48 hours and then processed for paraffin embedding (HistoStar™ Embedding Workstation). Sections 
of 7 µm of thickness obtained from the paraffin-embedded tissues (Thermo Scientific Microm HM355S 
microtome) were mounted on Superfrost™ Ultra Plus™ Adhesion slides (Thermo Scientific) and 
routinely stained with hematoxylin and eosin (Mayers Haematoxylin 1l, Leica, 3801582E and Eosin Y 
solution, aqueous (1 liter), Sigma-Aldrich, HT110232-1L) for histopathological examination. Sections 
were then stained with periodic acid–Schiff (PAS): Slides were incubated in freshly prepared periodic 
acid (0.5 %) for 15 min and rinsed and incubated for another 5 min in distilled water. The Schiff reagent 
(Sigma-Aldrich, 3952016-500ML) was added onto the slides and kept for 15 min at room temperature 
in dark. The sections were then washed in slightly lukewarm running tap water for 5 min, rinsed and 
incubated in distilled water for 2 min, and counterstained in Mayer’s hematoxylin (Mayers 
Haematoxylin 1l, Leica, 3801582E) for 1 min. After washing in running tap water for 5 min sections 
were dehydrated (95% EtOH, 100% EtOH, 100% EtOH, 3 min each, followed by two times xyleen for 
5 min) and mounted in DPX mounting medium (Sigma, 06522). Images were acquired on the Zeiss 
Axio Scan.Z1 using an x20 objective and ZEN 2 software. For exporting images the ZEN 2 software 
(Zeiss) was used. 
 
Immunofluorescence with tyramide signal amplification. Following antibodies were used for 
detecting the respective proteins: anti-Ki67 (rabbit, 1:1000, ThermoScientific, RM-9106-S, Clone SP6), 
anti-HLA-A (rabbit, 1:1250, Abcam, ab52922). Furthermore, the PerkinElmer Opal 4-Color Manual 
IHC Kit (PerkinElmer, NEL810001KT) was used for the tyramide signal amplification according to the 
manufacturer’s protocol. For introduction of the secondary-HRP the Envision+/HRP goat anti-Rabbit 
(Dako Envision+ Single Reagents, HRP, Rabbit, Code K4003) was used for antibodies raised in rabbit. 
The various proteins were detected using the OPAL 520 for ki67 and OPAL 690 for HLA-A. Images 
were acquired on the Zeiss Axio Scan.Z1 using a x20 objective and ZEN 2 software. For exporting 
38 
 
images the ZEN 2 software (Zeiss) and the software package QuPath Version: 0.1.2 was used ((68); 
https://github.com/qupath/qupath/wiki/Citing-QuPath). QuPath was also used for automatic cell 
detection using the DAPI channel and for subsequent creation of a detection classifier using all 55 given 
parameters resulting in the classification of Ki67 and HLA-A-double positive cells within the 
subpopulation of all HLA-A positive cells in the whole slide. 
 
Flow cytometric analysis of hematopoietic populations. Single-cell suspensions were prepared from 
peripheral blood, bone marrow, spleen, thymus and lymph nodes. Single cells were stained with 
antibodies against CD4-eFluor 450 (eBioscience), CD4-PECy7 (eBioscience) or CD4-PE (eBioscience), 
CD8-PerCp-eFluor 710 (eBioscience), CD8-APC-eFluor 780 (eBioscience) or CD8-APC 
(eBioscience), CD25-Alexa-488 (eBioscience) or CD25-APC (BD Pharmingen), CD44-Brilliant Violet 
510 (Biolegend) or CD44-PerCpCy5 (eBioscience) and hCD45-APC (eBioscience), as indicated and 
analyzed on a FACSCanto flow cytometer (BD Biosciences) or a MACSQuant VYB cell cytometer 
(Miltenyl Biotec). Data were analyzed using FlowJo software (Tree star).  
 
Quantitative real-time PCR. RNA was extracted from tissue and cells using the illustra RNAspin Mini 
Kit (GE Healthcare Life Sciences) as per manufacturer’s instructions. cDNA synthesis was carried out 
using GoScript (Promega) and real time quantitative performed using the GoTaq qPCR master mix 
(Promega) with the ViiA7 Real Time PCR system (Applied Biosystem). Quality control, primer 
efficiency and data analysis carried out using qbase+ software (Biogazelle). All gene expression was 
normalized using two housekeeping reference genes. Primers used for qPCR are listed in Supplementary 
Table S1. 
 
Proliferation assays and cell cycle analysis. T-ALL cell lines HPB-ALL, DND-41 and Jurkat were 
treated with the γ-secretase inhibitors DAPT and MRK-560 as indicated for 14 days. Cells were 
subcultured every 2-3 days by centrifugation and resuspension in fresh medium containing indicated 
compounds, as described previously (39). Total cell numbers and cell viability were determined by 
measuring FSC/SSC on a MACSQuant VYB cell cytometer (Miltenyl Biotec). Cell cycle assays were 
performed with the Click-iT™ Plus EdU Alexa Fluor™ 488 Flow Cytometry Assay Kit (Thermofisher 
scientific) as per manufacturer’s instructions. Briefly, 400 000 cells/ml were seeded, and treated with 
DMSO, 100, 300 and 1000nM MRK-560 for 5 days. Two hours before the indicated time point, the 
cells were pulsed with 10 µM EdU. Cells were collected, washed and fixed. The FxCycle™ Violet 
Ready Flow™ DNA stain (Thermofisher scientific) was added, followed by 30 min incubation time. 
Stained cells were analysed on the MACSQuant Vyb (Miltenyi). Data analysis was performed using 
FlowJo software (Tree Star). 
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Fig. S1. Psen1 deletion does not affect T-cell development.  
(A) Generation of Psen1 conditional knockout mice. (B) Representative western blot analysis of total 
thymus of C57BL/6 wildtype, Psen1f/f or CD2CrePsen1Δ/Δ mice for the different gamma-secretase 
subunits, Nicastrin, Psen1, Psen2, Aph1a, Pen2 and β-actin. (C) Quantification of protein levels of 
gamma-secretase subunits from B. (D) Gating strategy used for all flow-cytometry plots depicted in 
the manuscript. First, cells were gated according to physical parameters (FSC-A/SSC-A) in order to 
discard cell-debris and residual red blood cells. Next, cell singlets were gated (FSC-A/FSC-H) to 
discard clumps and doublets. These populations were then either assessed for GFP-levels or stained 
with the appropriate antibodies as described. All graphs show the mean values, error bars represent 
standard deviation. P values in C were calculated using one-way ANOVA. * P ≤ 0.05, ** P ≤ 0.01 and 
**** P ≤ 0.0001. 
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Fig. S2. Psen1 deletion does not affect engraftment in bone marrow transplants.  
(A) Representative flow-cytometry plots of ex vivo cultures of mouse pro-T cells derived from 
C57BL/6 wild type, Psen1f/f or CD2CrePsen1Δ/Δ mice stained with antibodies to CD44 and CD25. (B) 
Western blot analysis for Psen1 and β-actin of enriched hematopoietic stem and progenitor cells 
isolated from C57BL/6 wildtype, Psen1f/f or CD2CrePsen1Δ/Δ donor mice used for transplantation. (C) 
Quantification of GFP+ cells in thymi from mice transplanted with wildtype, Psen1f/f or 
CD2CrePsen1Δ/Δ progenitors expressing ΔEGF-NOTCH1-L1601P-ΔP 9 weeks after transplant. (D) 
Quantification of levels of circulating GFP+ cells in peripheral blood from mice transplanted with 
wildtype, Psen1f/f or CD2CrePsen1Δ/Δ progenitors expressing ΔEGF-NOTCH1-L1601P-ΔP 4 and 6 
weeks after transplant. All graphs show the mean values, error bars represent standard deviation. The 
P values in C were calculated using one-way ANOVA.  *** P ≤ 0.001 and **** P ≤ 0.0001.  
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Fig. S3. Tamoxifen does not affect leukemia progression.  
(A) Western blot analysis for Psen1 and β-actin in leukemic cells recovered from spleens ~2 weeks 
post-tamoxifen or vehicle treatment from mice transplanted with R26Cre-ERT2Psen1f/f progenitors 
expressing ΔEGF-NOTCH1-L1601P-ΔP. (B) Western blot analysis for Psen1, Psen2 and β-actin in 
leukemic cells recovered from a vehicle treated spleen, or spleens after ~1 week post-tamoxifen 
treatment and two mice that developed leukemia after tamoxifen treatment in mice transplanted with 
R26Cre-ERT2Psen1f/f progenitors expressing ΔEGF-NOTCH1-L1601P-ΔP. (C) Kaplan-Meier survival 
curves of mice transplanted with C57BL/6 wildtype progenitors expressing ΔEGF-NOTCH1-L1601P-
ΔP treated either with vehicle or tamoxifen (100 mg/kg/day tamoxifen by I.P. injection on 5 
consecutive days). All graphs show the mean values, error bars represent standard deviation. The P 
values in C were calculated using the log-rank test.  
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Fig. S4. MRK-560 shows selectivity for PSEN1 over PSEN2.  
Quantification of NICD1 generation in MEFs expressing PSEN1 or PSEN2 γ-secretase complexes in 
response to MRK-560 treatment (n=3). 
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Fig. S5. Treatment of patient derived xenograft samples with MRK-560.  
(A) Kaplan-Meier survival curves of mice transplanted with patient sample XC65 treated with vehicle 
or MRK-560 for 14 days. Treatment was started when 1% hCD45+ cells were detected in the blood. 
(B) Leukemia burden assessed by human CD45 staining of peripheral blood following 14 days 
treatment with 30 μmol/kg MRK-560 or vehicle by subcutaneous injection (grey box) of PDX XB47. 
(C) quantitative real time PCR analysis of PSEN1 levels. (D) Human HLA-A immunofluorescent 
staining of spleen sections from PDX XC63 taken immediately following 14 days treatment with 30 
μmol/kg MRK-560 or vehicle by subcutaneous injection (Scale bar = 500 μm). (E) Representative 
higher magnification of Human HLA-A and Ki67 immunofluorescent staining of spleen sections from 
PDX XC63 taken immediately following 14 days treatment with 30 μmol/kg MRK-560 or vehicle by 
subcutaneous injection. Associated quantification of Ki67 in HLA-A positive cells comparing MRK-
560 (n=4) and Vehicle (n=4) treated mice (Scale bar = 50 μm). (F) Leukemia burden assessed by 
bioluminescence after two rounds of 30 μmol/kg MRK-560 treatment of PDX XC65, with second 
round of treatment begun during relapse to determine if sensitivity is maintained to MRK-560. 
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Fig. S6. Long term treatment with MRK-560 leads to significantly less gastrointestinal toxicity 
compared to DBZ.  
(A) Representative images of Periodic Acid-Schiff staining of intestines from mice treated with MRK-
560 or the broad-spectrum γ-secretase inhibitor Dibenzazepine (DBZ) for 4 weeks to assess the 
number of secretory goblet cells. Scale bars represent 100 μm. (B) Quantification of the number of 
goblet cells per cm villus with 10 villi counted per mouse (MRK-560 n=5 and DBZ n=4, respectively). 
(C) Weights of mice over the 4 week treatment period. (D) Visible hair loss in DBZ treated mice 
compared to MRK-560 treated mice at end of 4 week treatment period. 
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Table S1. Primers used for qPCR. 
Gene Forward Reverse 
DTX1 CGCAAGACCAAGAAGAAGC CTCATCAGGTGGGTTTTTCAC 
MYC CTCGGATTCTCTGCTCTCCT TTTCCACAGAAACAACATCG 
NOTCH3 TTACGACTGTGCCTGTCTTCC TATAGGTGTTGACGCCATCC 
HPRT TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT 
TBP CGGCTGTTTAACTTCGCTTC CACACGCCAAGAAACAGTGA 
 
 
 
Table S2.  T-ALL cell lines and patient derived xenograft models. 
 Mutations Subtype 
Cell lines  
HPB-ALL NOTCH1(L1575P), NOTCH1 PEST indel 
FBXW7(R347H), WT1(S189*), TP53(R141C) 
TLX3 
DND-41 NOTCH1(L1594P), NOTCH1(D1610V), 
NOTCH1 PEST indel, IL7R indel, NRAS(Q61H) 
TLX3 
Jurkat PTEN deletion, TP53 R64*, 
NOTCH1 ins1740QAVEPPPPAQLHFMYVA 
TAL1 
 
PDX samples 
 
XC63 NOTCH1(L1678P), NOTCH1(Q2459*), 
JAK3(M511I)  
immature 
XC65 NOTCH1(A2438fs*), JAK1 (R724H) immature 
389E  NOTCH1(L1600P), NOTCH1(P2514fs*), 
JAK3(M511I), DNM2 
immature 
XB47 NOTCH1(L1600P), NOTCH1(Y2490*), 
RPL10(R98S), CNOT3(R745ins), 
del(9)(p21p21) 
TAL1 
 
